ALS and Frontotemporal Dementia Antigens

Overview

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent a clinicopathological spectrum unified by the presence of transactive response DNA-binding protein 43 kDa (TDP-43) pathology in the majority of cases; whereas ALS preferentially affects upper and lower motor neurons leading to progressive paralysis, FTD encompasses a group of neurodegenerative disorders characterized by atrophy of the frontal and temporal lobes with consequent behavioral, language, and executive dysfunction. The discovery that TDP-43 constitutes the principal component of ubiquitinated inclusions in both sporadic ALS and the most common pathological subtype of FTD (frontotemporal lobar degeneration with TDP-43 inclusions, FTLD-TDP) fundamentally established these disorders as divergent clinical expressions of a shared proteinopathy. The GGGGCC hexanucleotide repeat expansion in the noncoding region of chromosome 9 open reading frame 72 (C9orf72) represents the most prevalent genetic cause of both familial ALS and FTD, accounting for approximately 40% of familial ALS and 25% of familial FTD cases, thereby providing compelling genetic evidence for the ALS-FTD disease continuum. Antigen products targeting RNA-binding proteins, dipeptide repeat species, and lysosomal pathway components serve as indispensable molecular tools for dissecting disease heterogeneity and developing biomarker assays across the sporadic and familial ALS/FTD spectra.

The pathological mechanism linking ALS and FTD converges upon dysregulated RNA homeostasis and impaired protein quality control, wherein the nuclear depletion and cytoplasmic mislocalization of TDP-43 result in a catastrophic loss of normal RNA processing functions concomitant with a toxic gain-of-function mediated by cytoplasmic aggregate formation. Fused in sarcoma (FUS), another RNA-binding protein genetically linked to familial ALS, undergoes similar nucleocytoplasmic redistribution with formation of characteristic filamentous inclusions that exhibit ultrastructural features distinct from TDP-43 aggregates. C9orf72-related disease introduces a unique pathological axis through repeat-associated non-AUG (RAN) translation, which generates five distinct dipeptide repeat proteins—poly-glycine-alanine (poly-GA), poly-glycine-proline (poly-GP), poly-glycine-arginine (poly-GR), poly-proline-alanine (poly-PA), and poly-proline-arginine (poly-PR)—that accumulate as insoluble cytoplasmic and intranuclear inclusions exerting convergent toxicity on nucleocytoplasmic transport, ribosomal biogenesis, and stress granule dynamics. Autoreactive T and B cell activation at the neuromuscular junction has been documented in ALS patients, with evidence of complement-mediated synaptic loss and antibody-driven motor neuron pathology, while FTD-associated autoimmune phenomena, including anti-programmed cell death protein 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) paraneoplastic presentations, underscore the immunological dimensions of these neurodegenerative disorders.

The selection of antigens for ALS and FTD research and diagnostic assay development necessitates careful consideration of pathological subtype specificity, target conformation, and intended analytical platform. Recombinant full-length RNA-binding proteins, including wild-type and disease-associated mutant variants of TDP-43 and FUS, support the development of quantitative immunoassays for measuring native and misfolded protein species in cerebrospinal fluid (CSF) and serum, whereas synthetic peptides corresponding to the GGGGCC repeat expansion and purified dipeptide repeat proteins enable the generation and validation of C9orf72 expansion-specific antibodies. Cell-based assays incorporating pathologically modified antigen substrates—such as phosphorylated TDP-43 at serine 409/410 or stress granule-associated TDP-43 conformations—provide enhanced diagnostic specificity for distinguishing ALS-FTD spectrum disorders from other neurodegenerative proteinopathies. The majority of validated ALS and FTD biomarker assays utilize enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence (ECL), and single-molecule array (Simoa) platforms, with CSF specimens representing the primary matrix for analyte detection, though recent advances in blood-based assays for neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNFH) have expanded the repertoire of accessible specimen types for clinical screening and therapeutic monitoring.

Fig. 1 ALS and Frontotemporal Dementia Immunopathogenic Mechanisms

Classical Targets

The classical targets for ALS and frontotemporal dementia antigen development encompass the core RNA-binding proteins, dipeptide repeat species, and genetic risk factors that define the molecular taxonomy of the ALS-FTD disease spectrum. Selection of the appropriate antigen target should be guided by the intended application, whether for subclassifying TDP-43-positive versus FUS-positive versus tau-positive pathological subtypes, screening for C9orf72 repeat expansion carriers, developing genetic testing companion diagnostics, or investigating autophagy-lysosomal and ubiquitin-proteasome pathway dysfunction.

Classical Targets List

TDP-43

Localization and Function

Transactive response DNA-binding protein 43 kDa (TDP-43) is encoded by the TARDBP gene on chromosome 1 and is predominantly localized to the nucleus under physiological conditions, where it participates in constitutive and alternative splicing regulation, mRNA stability control, and microRNA biogenesis through its C-terminal glycine-rich domain and two RNA recognition motifs (RRM1 and RRM2). In ALS and approximately 50% of FTD cases, TDP-43 undergoes characteristic post-translational modifications including C-terminal fragmentation, hyperphosphorylation at serine residues 409 and 410, and ubiquitination, resulting in its depletion from the nucleus and accumulation within phospho-TDP-43-positive cytoplasmic inclusions throughout the central nervous system. These pathological TDP-43 aggregates are observed not only in motor neurons and cortical pyramidal neurons but also in glial cells, including oligodendrocytes and astrocytes, suggesting a propagated, non-cell-autonomous mechanism of disease spread that implicates both neuronal and glial compartments in the progressive pathological cascade.

Immunological Relevance

TDP-43 represents the defining pathological substrate of the overwhelming majority of sporadic ALS cases and the most common molecular subtype of FTD, with anti-TDP-43 autoantibodies detectable in the CSF of affected individuals at varying frequencies depending on disease stage and analytical platform sensitivity. Recombinant full-length TDP-43 and its truncated C-terminal fragments (25 kDa and 35 kDa species) serve as essential reagents for the development of sandwich ELISAs, immunoprecipitation assays, and cell-based assays that distinguish pathologically phosphorylated TDP-43 from its native nuclear counterpart. The conformation-specific epitopes exposed upon TDP-43 misfolding and aggregation have been exploited for the generation of monoclonal antibodies targeting disease-associated TDP-43 conformations, with particular utility for immunohistochemical classification of FTLD-TDP subtypes (types A through D) and for quantitative biomarker development aimed at monitoring disease progression and therapeutic response in clinical trials targeting TDP-43 proteinopathy.

FUS

Localization and Function

Fused in sarcoma (FUS), also designated as TLS (translocated in liposarcoma), is a multifunctional DNA/RNA-binding protein encoded by the FUS gene on chromosome 16 that localizes predominantly to the nucleus, where it participates in transcriptional regulation, DNA damage repair through homologous recombination, and the transport of mRNA to dendritic spines for local translation at synapses. In contrast to TDP-43 proteinopathy, FUS-associated ALS and FTD (collectively termed FUS-proteinopathy) is characterized by the cytoplasmic retention of full-length, non-fragmented FUS protein that lacks the pathological hyperphosphorylation signature seen in TDP-43 inclusions; instead, FUS aggregates exhibit a distinctive filamentous ultrastructure with a straight tubular morphology of approximately 12 nm diameter, as revealed by cryo-electron microscopy studies of patient-derived aggregates. Mutations in the nuclear localization signal (NLS) region of FUS, particularly at arginine residues 495, 514, 521, and 522, impair the transportin-mediated nuclear import pathway and result in pronounced cytoplasmic FUS accumulation with consequent loss of nuclear RNA processing functions.

Immunological Relevance

FUS proteinopathy defines a distinct molecular subclass of familial ALS (approximately 4% of cases) and rare cases of FTD, with anti-FUS antibodies serving as critical diagnostic reagents for immunohistochemical subclassification of frontotemporal lobar degeneration with FUS pathology (FTLD-FUS), which encompasses atypical FTLD with ubiquitinated inclusions (aFTLD-U), neuronal intermediate filament inclusion disease (NIFID), and basophilic inclusion body disease (BIBD). Recombinant FUS proteins, including wild-type and NLS-mutant variants, enable the development of assays that discriminate FUS-driven pathology from TDP-43 and tau proteinopathies, thereby supporting precise molecular neuropathological diagnosis. The development of anti-FUS monoclonal antibodies that specifically recognize the aggregated, fibrillar conformation of cytoplasmic FUS without cross-reactivity to nuclear FUS holds significant promise for both research applications investigating the prion-like propagation of FUS aggregates and clinical biomarker programs targeting this molecular subtype.

C9orf72

Localization and Function

Chromosome 9 open reading frame 72 (C9orf72) is a highly conserved protein that localizes to the cytosol, lysosomal membranes, and endosomal compartments, where it functions as a guanine nucleotide exchange factor (GEF) for Rab-GTPases involved in autophagy initiation, lysosomal biogenesis, and endocytic trafficking; loss of C9orf72 protein function due to the hexanucleotide repeat expansion results in impaired autophagic flux and accumulation of autophagic substrates. The GGGGCC repeat expansion, which can extend to several thousand repeats in affected individuals compared to fewer than 30 repeats in healthy controls, occurs within the first intron of the C9orf72 gene and leads to reduced C9orf72 protein expression (haploinsufficiency), accumulation of repeat-containing RNA foci within the nucleus, and RAN translation of all six reading frames into the five dipeptide repeat proteins. Poly-GR and poly-PR arginine-containing dipeptides exhibit particularly potent toxicity through disruption of nucleocytoplasmic transport, phase separation of RNA-binding proteins, and direct membrane permeabilization, whereas poly-GA forms abundant p62-positive skein-like inclusions that are a pathological hallmark of C9orf72-related disease.

Immunological Relevance

The C9orf72 hexanucleotide repeat expansion constitutes the most common known genetic cause of both ALS and FTD, and the dipeptide repeat proteins generated through RAN translation represent neoantigens unique to expansion carriers, thereby providing highly specific biomarker targets for diagnostic stratification. Anti-poly-GA, anti-poly-GP, and anti-poly-GR antibodies have been developed for detecting dipeptide repeat protein accumulation in CSF and serum, with poly-GP showing particular promise as a fluid biomarker due to its detection in CSF at elevated levels in both symptomatic carriers and presymptomatic individuals destined to develop disease. Recombinant dipeptide repeat proteins and synthetic peptides of varying repeat lengths serve as essential antigens for the generation of repeat-specific antibodies, the development of quantitative immunoassays for measuring dipeptide repeat burden, and the screening of potential therapeutic interventions aimed at suppressing RAN translation or promoting dipeptide repeat clearance in C9orf72-related ALS and FTD.

Tau (FTLD-tau)

Localization and Function

Microtubule-associated protein tau (MAPT), encoded by the MAPT gene on chromosome 17, is an axonally enriched phosphoprotein that exists as six alternatively spliced isoforms containing either three (3R) or four (4R) microtubule-binding repeat domains; tau promotes microtubule assembly and stabilization, facilitates axonal transport of organelles and cargo, and participates in signaling pathways regulating neuronal viability and synaptic plasticity. Frontotemporal lobar degeneration with tau pathology (FTLD-tau) encompasses a heterogeneous group of disorders including Pick disease (characterized predominantly by 3R tau inclusions forming Pick bodies), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP, both with 4R tau predominance), and argyrophilic grain disease (AGD), each exhibiting distinct anatomical patterns of neurodegeneration, glial pathology, and isoform-specific tau aggregation. Unlike Alzheimer's disease (AD) tauopathy, which contains equivalent proportions of 3R and 4R tau isoforms within neurofibrillary tangles, FTLD-tau subtypes demonstrate selective enrichment of either 3R or 4R isoforms, a biochemical distinction with profound implications for both diagnostic assay design and therapeutic antibody development.

Immunological Relevance

The immunological landscape of FTLD-tau has been transformed by the development of anti-tau monoclonal antibodies, including semorinemab (an IgG4 antibody targeting extracellular tau), gosuranemab (targeting N-terminal tau epitopes), and zagotenemab (targeting the microtubule-binding region), which have advanced through clinical trials for progressive supranuclear palsy and other tauopathies with varying degrees of efficacy. The cerebrospinal fluid p-tau181 to total tau ratio serves as an established biomarker for discriminating FTLD-tau from AD and from FTLD-TDP subtypes, with emerging evidence supporting the utility of p-tau217, p-tau205, and other site-specific phosphorylation markers for molecular subclassification. Recombinant tau proteins, including individual 3R and 4R isoforms, pathologically phosphorylated tau species, and preformed fibrillar tau preparations, constitute critical antigen reagents for the development of isoform-specific immunoassays, the generation of conformation-selective antibodies that distinguish tau aggregate strains, and the standardization of diagnostic platforms for clinical trial enrollment and patient stratification in FTLD-tau.

Progranulin

Localization and Function

Progranulin (PGRN), also known as granulin-epithelin precursor (GEP) or proepithelin, is a secreted glycoprotein of approximately 88 kDa that undergoes proteolytic cleavage by elastase and other serine proteases into individual granulin peptides; it is expressed in neurons, microglia, macrophages, and neutrophil granules, and functions as a growth factor promoting neuronal survival, wound healing, and anti-inflammatory signaling through suppression of tumor necrosis factor-alpha (TNF-alpha) and modulation of toll-like receptor responses. Loss-of-function mutations in the granulin precursor gene (GRN) on chromosome 17 account for approximately 25% of familial FTD cases and 5-10% of sporadic FTD, resulting in progranulin haploinsufficiency that leads to reduced protein levels, dysregulated lysosomal function, and secondary TDP-43 accumulation with consequent FTLD-TDP pathology. The convergence of GRN-related and C9orf72-related disease upon lysosomal and autophagic dysfunction highlights the central importance of the endolysosomal pathway in FTD pathogenesis, with progranulin-deficient microglia exhibiting impaired phagocytic capacity and exaggerated inflammatory responses that accelerate neurodegeneration.

Immunological Relevance

Circulating progranulin levels in serum and plasma serve as a robust, GRN mutation-specific biomarker, with symptomatic carriers and presymptomatic GRN mutation carriers demonstrating approximately 50% reduction in progranulin concentration compared to non-carrier controls, thereby enabling predictive genetic counseling and therapeutic trial enrollment. CSF progranulin measurements, while technically more demanding due to low baseline concentrations, have shown correlation with neurodegenerative burden and may complement serum measurements for monitoring disease progression and target engagement in progranulin replacement therapy trials. Recombinant human progranulin and its constituent granulin peptides are utilized as antigen substrates for the development of sensitive progranulin immunoassays, for investigating progranulin receptor signaling pathways (including sortilin and TNFR1/2), and for preclinical studies evaluating progranulin gene therapy, small molecule enhancers of progranulin expression, and recombinant protein replacement as disease-modifying therapeutic strategies for GRN-related FTD.

VCP

Localization and Function

Valosin-containing protein (VCP), also designated p97, is an evolutionarily conserved AAA+ ATPase that is ubiquitously expressed in nuclear and cytoplasmic compartments, where it functions as a central hub of protein quality control through its essential roles in endoplasmic reticulum-associated degradation (ERAD), ubiquitin-proteasome system (UPS) substrate processing, autophagosome maturation, mitochondrial quality control via mitophagy, and DNA damage response pathways. Mutations in the VCP gene on chromosome 9 cause inclusion body myopathy with Paget disease and frontotemporal dementia (IBMPFD), an autosomal dominant multisystem proteinopathy characterized by progressive muscle weakness, bone remodeling abnormalities, and behavioral-variant FTD with TDP-43 and ubiquitin-positive inclusions in the central nervous system. VCP-containing inclusions also co-localize with TDP-43, p62, and ubiquitin in sporadic ALS and FTD, indicating that VCP dysfunction may constitute a convergence point for multiple proteinopathy pathways through its critical function in segregating and processing ubiquitinated substrates for proteasomal degradation.

Immunological Relevance

The identification of VCP mutations as the cause of IBMPFD has established anti-VCP antibodies as essential reagents for diagnostic screening programs targeting hereditary proteinopathy overlap syndromes, particularly in patients presenting with the characteristic triad of myopathy, Paget disease, and cognitive decline. Recombinant VCP protein, including wild-type and disease-associated mutant variants (most commonly R93C, R155C, and R155H), supports the development of functional ATPase assays for measuring VCP enzymatic activity, the generation of antibodies specific for VCP in its ATP-bound versus ADP-bound conformational states, and the investigation of VCP adaptor protein interactions (including p47, NPL4, and UFD1) that mediate substrate recognition and processing. VCP-targeted therapies, including allosteric inhibitors of VCP ATPase activity currently under investigation in oncology, may offer repurposing opportunities for neurodegenerative proteinopathies characterized by impaired protein clearance and VCP dysfunction.

SOD1

Localization and Function

Copper-zinc superoxide dismutase 1 (SOD1) is a cytosolic metalloenzyme of approximately 32 kDa (homodimer) that catalyzes the dismutation of superoxide radicals into hydrogen peroxide and molecular oxygen, representing a critical component of cellular antioxidant defense; SOD1 also localizes to the mitochondrial intermembrane space, where it participates in mitochondrial reactive oxygen species (ROS) detoxification and cellular respiration quality control. Mutations in the SOD1 gene on chromosome 21 were the first genetic cause identified for familial ALS, accounting for approximately 20% of familial cases and conferring a toxic gain-of-function rather than loss of enzymatic activity; SOD1-associated ALS results from the accumulation of misfolded, aggregated SOD1 species that adopt a non-native beta-sheet-rich conformation and form toxic oligomers, protofilaments, and mature inclusions within motor neurons and glial cells. The pathological SOD1 aggregates in both mutant SOD1 transgenic models and human SOD1-ALS exhibit prion-like propagation properties, with evidence of intercellular transmission and seeded aggregation that implicates non-cell-autonomous spread through the neuroaxis.

Immunological Relevance

SOD1 distinguishes itself as the canonical genetic target for familial ALS companion diagnostics, with anti-SOD1 antibodies serving critical functions in genetic counseling confirmation, preclinical therapeutic studies, and the emerging field of SOD1-targeted gene silencing therapies including tofersen, an antisense oligonucleotide approved for SOD1-ALS treatment. Cerebrospinal fluid SOD1 levels correlate with disease progression in SOD1 mutation carriers, and conformation-specific antibodies that recognize misfolded SOD1 without binding to the natively folded enzyme have enabled the development of assays detecting toxic oligomeric species in biological fluids. Recombinant wild-type and mutant SOD1 proteins (encompassing the more than 180 identified pathological mutations including A4V, G93A, and L144F) constitute essential antigen reagents for SOD1 immunoassay development, aggregation kinetic studies, and the evaluation of therapeutic strategies aimed at reducing SOD1 expression, stabilizing native SOD1 conformation, or accelerating clearance of aggregated SOD1 species.

Ubiquilin-2

Localization and Function

Ubiquilin-2 (UBQLN2) is an X-linked member of the ubiquilin family that shuttles between the cytoplasm and nucleus, functioning as a critical adaptor protein that links polyubiquitinated substrates to the 26S proteasome for degradation and regulates autophagosome maturation through interactions with LC3 and the autophagic machinery. Mutations in the UBQLN2 gene, including proline-rich repeat region alterations (P497H, P497S, P506T) and missense mutations throughout the gene, cause X-linked dominant ALS and FTD with complete penetrance in males and variable penetrance in females, establishing ubiquilin-2 as a key component of the protein quality control network whose dysfunction impairs both proteasomal and autophagic degradation pathways. UBQLN2 mutations result in the accumulation of characteristic ubiquitin-positive, TDP-43-positive, p62-positive, and optineurin-positive skein-like inclusions in cortical and spinal motor neurons, with the additional presence of UBQLN2-positive lentiform hyaline inclusions that distinguish UBQLN2 pathology from other ALS-FTD molecular subtypes.

Immunological Relevance

Anti-ubiquilin-2 antibodies are indispensable reagents for X-linked ALS screening programs, particularly in families demonstrating male-to-male transmission exclusion and X-linked inheritance patterns with variable female penetrance, thereby enabling precise genetic counseling and cascade testing of at-risk relatives. The physical and functional interaction between ubiquilin-2 and other ALS-associated proteins including TDP-43, optineurin, and p62 positions anti-UBQLN2 antibodies as valuable tools for investigating the convergence of proteasomal and autophagic degradation pathways in ALS-FTD pathogenesis. Recombinant ubiquilin-2 protein and its UBA (ubiquitin-associated), UBL (ubiquitin-like), and STI1 (heat shock chaperone-binding) domain constructs support the development of protein-protein interaction assays, the generation of domain-specific antibodies, and the screening of therapeutic candidates aimed at restoring ubiquilin-2-mediated substrate delivery to the proteasome and autophagy pathways.